PAGES COPYRIGHT©2017CQDCYL.CN    渝ICP备17012990号    POWERED BY 300.CN  【MANAGE

NEWS

Immunotherapy can almost completely eliminate allograft rejection

Classification:
Industry dynamics
Author:
Source:
2017/12/15 09:51
Page view
[Abstract]:
AccordingtoarecentreportfromtheSeattleChildren'sResearchInstituteattheannualmeetingoftheAmericanAssociationofHematology,aPhaseIIclinicaltrialshowedthatAbataceptwasabletoalmostcompletelycurethelethalit
According to a recent report from the Seattle Children's Research Institute at the annual meeting of the American Association of Hematology, a Phase II clinical trial showed that Abatacept was able to almost completely cure the lethality of patients with advanced cancer or blood disorder after stem cell transplantation Of graft-versus-host disease (GvHD). Abatacept reduced the incidence of toddlers and adult patients to 32% and 3%, respectively, when used in combination with conventional medicines. In short, the therapy can significantly improve the patient's health and survival rate.   
 
Acute GvHD is a fatal disease that occurs as a result of stem cell transplantation. The reason for this is that the donor's T cells attack the patient's organs, such as the skin, liver, Shenzhen, lung, and digestive tract. Asymptomatic donor cells from non-transplant donor patients, the incidence of these diseases as high as 80%, of which half of the patients will die.
 
"Due to the serious threat of the disease, we need to develop new tools to ensure the safety of patient transplants," said Dr. Leslie Kean, the study's lead author. Initially, Kean found that abatacept had a significant effect on the treatment of rheumatoid arthritis, so he wondered if the drug could also treat GvHD. For rheumatoid arthritis, abatacept reduces joint inflammation by inhibiting T-cell activation and blocking a series of reactions.
 
Similarly, some studies by Kean et al. Found that abatacept blocked the activity of specific T cells following transplant surgery. In their theory, excessive activation of effector T cells and attacking the patient's immune system are the major causes of GvHD.
 
"It's heartbreaking for a transplant surgeon to find out if we have found a cancer that has been cured by a transplant but has died of GvHD," says Kean. "So if we can find a safe cure , Resulting in a significant reduction in the chances of developing GvHD in patients, a tremendous breakthrough for the entire field of stem cell transplantation. "
Key words: